Neuroprotective and neurotrophic efficacy of Ginkgo biloba extracts against 3-nitropropionic acid-induced oxidative stress in a rat model of Huntington’s disease
Objective: The present study examined the potential neuroprotective and neurotrophic efficacy of GBE against 3-nitropropionic acid (3-NP)-induced oxidative stress in a rat model of HD…Magnetic Resonance Spectroscopy Evaluation of Neuronal Integrity and Astrocytosis in a Phase 2 Study of Laquinimod as a Treatment for Huntington Disease (LEGATO-HD)
Objective: Evaluate the effect of laquinimod on putaminal and frontal white matter markers of neuronal integrity and astrocytosis using magnetic resonance spectroscopy (MRS) in patients…Exploring the effects of intrastriatal AAV5-miHTT therapy on MRS signal and mutant huntingtin levels in the Q175FDN mouse model of HD
Objective: To assess the effects of intrastriatal AAV5-miHTT therapy on MRS signal and mutant huntingtin levels in the Q175FDN mouse model of HD. Background: Huntingtin…Reliability, feasibility and validity of a novel digital monitoring platform assessing cognitive and motor symptoms in people with Stage I and II Huntington’s disease (HD)
Objective: To determine the reliability and convergent validity of a novel digital monitoring platform offering objective, daily assessment of cognitive and motor symptom severity in…Grey-matter volume changes underpinning irritability and aggression in early manifest Huntington’s disease
Objective: To explore grey-matter volume (GMV) differences between early-stage Huntington's disease (HD) patients with and without significant irritability/aggression symptoms (IAs) and to assess it association…Normative Curves for Selected Unified Huntington Disease Rating Scale Measures
Objective: To examine the effects of natural aging for those without Huntington disease (HD) gene expansion and to develop normative curves by age, sex, and…A Unified Staging System for Prodromal and Manifest Huntington’s disease
Objective: To develop an integrated staging methodology for Prodromal and Manifest Huntington’s disease (HD). Background: Once HD is diagnosed clinically (also known as, motor-onset/manifest), HD…Seeking regulatory feedback on novel clinical outcome assessments: a case example from the Huntington’s Disease – Regulatory Science Consortium (HD-RSC)
Objective: To align with regulators on the utility and development strategy of novel clinical outcome assessments for use in Huntington’s disease (HD) clinical trials. Background:…Prevalence of Huntington’s Disease in Sardinia, Italy
Objective: We have performed a service-based epidemiological analysis extended to the population residing in Sardinia. The socio-cultural isolation of this large Mediterranean island makes genetic…Huntington’s disease: A case review of Sub-Saharan Africans with diverse origins
Objective: To characterise the Huntingtons disease phenotype in Sub-saharan Africans. Background: Huntington’s disease (HD) is a debilitating neurodegenerative illness that leads to diminished cognitive function,…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.